Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 8.98

Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (2002) 6.51

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med (2015) 4.97

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst (2007) 4.03

Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res (2010) 3.35

The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res (2007) 3.04

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol (2010) 2.93

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res (2009) 2.68

See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol (2006) 2.62

Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res (2005) 2.39

TLR signaling by tumor and immune cells: a double-edged sword. Oncogene (2008) 2.18

Skin metastasis: a pathologist's perspective. J Cutan Pathol (2009) 2.05

Infectious tolerance and the long-term acceptance of transplanted tissue. Immunol Rev (2006) 1.88

Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res (2007) 1.88

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther (2007) 1.70

Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Immunol Rev (2006) 1.61

Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest (2007) 1.56

Imiquimod in the treatment of breast cancer skin metastasis. J Clin Oncol (2014) 1.51

The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist (2008) 1.47

Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene (2008) 1.46

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res (2012) 1.46

Treatment of mammary and extramammary Paget's skin disease with topical imiquimod. J Dermatolog Treat (2006) 1.44

Cutaneous manifestations of breast carcinoma. Dermatol Ther (2010) 1.35

Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol Rev (2006) 1.27

A key role for TGF-beta signaling to T cells in the long-term acceptance of allografts. J Immunol (2007) 1.27

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol (2014) 1.19

Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation. J Immunol (2007) 1.12

Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer (2007) 1.04

In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol (2004) 1.03

Patterns of skin and soft tissue metastases from breast cancer according to subtypes: relationship between EGFR overexpression and skin manifestations. Oncology (2011) 0.94

Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance. Clin Breast Cancer (2013) 0.83

Toll-like receptor mediated regulation of breast cancer: a case of mixed blessings. Front Immunol (2014) 0.83

Hair follicle mesenchyme-associated PD-L1 regulates T-cell activation induced apoptosis: a potential mechanism of immune privilege. J Invest Dermatol (2013) 0.80

Modulation of tumor tolerance in primary central nervous system malignancies. Clin Dev Immunol (2012) 0.79

Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report. Oncol Lett (2014) 0.78

Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy. Breast Cancer Res Treat (2014) 0.77

Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient. Tumori (2013) 0.76